Your Article Summary
See Latest ArticlesOral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making
Expert Opinion in Pharmacotherapy, 06/30/09
Volavka J et al. - The classification of antipsychotics into the two groups is no longer useful. The treatment selection for an individual patient should focus on the suitability of an individual antipsychotic for that patient rather than on the group membership of the drug.
Today in Psychotherapy/analysis...keeping you current
Receive free subspecialty "5-minute updates" via email
The contribution of active medication to combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis
Acta Psychiatrica Scandinavica, 11/23/09
Executive functions in children with Autism Spectrum Disorders
Brain and Cognition, 11/12/09
Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial
Journal of the American Academy of Child and Adolescent Psychiatry, 11/09/09
Today in Schizophrenia/Psychosis...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder
Schizophrenia Research, 11/18/09
Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate
Asian Journal of Psychiatry, 11/09/09